<DOC>
	<DOCNO>NCT01868880</DOCNO>
	<brief_summary>The aim prospective , randomize control trial evaluate use ivabradine combination low-dose beta-blocker ( bisoprolol ) versus up-titration beta-blocker ( bisoprolol ) obtain heart rate ( HR ) control reduction RV pace single-chamber dual chamber ICD recipient HF patient moderate severe leave ventricular dysfunction ( FE ≤ 40 % ) heart rate ≥ 70 bpm sinus rhythm 12-months follow . Besides investigator want assess combination ivabradine low-dose beta-blocker ( bisoprolol ) versus up-titration beta-blocker ( bisoprolol ) may determine low degree leave ventricular dysfunction progression , reduction ventricular arrhythmia burden ICD appropriate therapy occurrence improvement quality life ICD heart failure patient .</brief_summary>
	<brief_title>Effect Ivabradine Beta-blockers Combination Versus Beta-blockers Up-titration Right Ventricular Pacing</brief_title>
	<detailed_description>Background High heart rate ( HR ) represent per se risk factor cardiovascular mortality heart failure ( HF ) progression , despite optimal HF therapy . Beta-blockers remain therapy choice patient systolic HF , may worsen atrioventricular ( AV ) conduction increase right ventricular ( RV ) pace percentage . Several study demonstrate detrimental effect RV pace cardiac function . Percent RV pace &gt; 40-50 % independent predictor death hospitalization HF implantable cardioverter-defibrillator ( ICD ) patient , particularly preexistent leave ventricular dysfunction.1,2 Cumulative RV pace &gt; 2 % ejection fraction ( EF ) &lt; 40 % independent predictor Ventricular Tachycardia ( VT ) /Ventricular Fibrillation ( VF ) occurrence ICD patients.3 Therefore reduction cumulative RV pacing far possible achieve ICD patient . Ivabradine specific inhibitor If current sinus node , induces selective dose dependent HR reduction ; pure HR lower agent without effect AV conduction contractility.4 In HF patient implant ICD ivabradine could act heart rate control drug combination beta-blocker without increase right ventricular ( RV ) pace percentage may option reduce left-ventricular dysfunction progression ventricular arrhythmia burden appropriate ICD therapy . Aim The aim prospective , randomize control trial evaluate use ivabradine combination low-dose beta-blocker ( bisoprolol ) versus up-titration beta-blocker ( bisoprolol ) obtain heart rate ( HR ) control reduction RV pace single-chamber dual chamber ICD recipient HF patient moderate severe leave ventricular dysfunction ( FE ≤ 40 % ) heart rate ≥70 bpm sinus rhythm 12-months follow . Besides want assess combination ivabradine low-dose beta-blocker ( bisoprolol ) versus titration beta-blocker ( bisoprolol ) may determine low degree leave ventricular dysfunction progression , reduction ventricular arrhythmia burden ICD appropriate therapy occurrence improvement quality life ICD heart failure patient . Endpoints study Primary endpoint : Right ventricular pace percentage increase &gt; 50 % Cardiovascular death Heart failure decompensation Crossover due worsen heart failure . Secondary endpoint : Ejection fraction decrease &lt; 5 % Left Ventricular End-Systolic Volume decrease &lt; 15 % . Ventricular arrhythmias ICD appropriate therapy reduction . Heart rate variability improvement NYHA Classification improvement Minnesota Living With Heart Failure Questionnaire ( MLHFQ ) total score reduction . Right ventricular pacing percentage . Composite endpoint : cardiovascular death hospitalization due worsen heart failure . Crossover rate due worsen heart failure Study protocol : Baseline assessment : Clinical visit : demographic data , risk factor cardiovascular disease , primary cause heart failure , NYHA class , comorbidities , echocardiographic parameter , drug therapy , cardiovascular hospitalization last year . Rest ECG ( assessment rest heart rate , presence sinus rhythm device-induced rhythm , QRS duration ) ; Blood pressure measurement ; Electronic device control ( assessment right ventricular stimulation percentage ; electrical parameter arrhythmias diagnostic data ) ; Echocardiogram ( assessment leave ventricular end-diastolic end-systolic volume , leave ventricular ejection fraction ) ; MLHFQ Assignment consecutive patient treatment ivabradine plus beta-blocker ( bisoprolol ) beta-blocker ( bisoprolol ) titration . Mean Heart Rate Target 55-70 bpm group . Ivabradine administer dose 5 mg twice daily addition low dose beta-blocker ( bisoprolol 1,25 2,5 mg ) . After four week treatment ivabradine eventually lower 2,5 mg twice daily presence side effect ( phosphenes , diplopia , headache dizziness ) . Beta blocker Bisoprolol up-titrated biweekly start initial dose 1,25-2,5 mg daily max dose 10 mg daily maximum tolerate dose . Patients controlled office follow-up visit 3 , 6 12 month , addition Remote Monitoring program clinical data trend review least every 15 day soon possible whenever Remote Monitoring alert notification receive . Besides every 15 day patient receive telephone contact order evaluate clinical state uptitrate beta blocker therapy base mean heart rate detect trough remote control ICD . Three month in-office follow-up : Clinical visit : symptom , NYHA class , drug therapy , cardiovascular hospitalization last three month . Rest ECG ( assessment rest heart rate , presence sinus rhythm device-induced rhythm , QRS duration ) ; Blood pressure measurement ; Echocardiogram ( assessment leave ventricular end-diastolic end-systolic volume , leave ventricular ejection fraction ) ; Electronic device control ( assessment right ventricular stimulation percentage ; electrical parameter arrhythmias diagnostic data ) . Six month office follow-up : Clinical visit : NYHA class , comorbidities , echocardiographic parameter , drug therapy , cardiovascular hospitalization last three month . Rest ECG ( assessment rest heart rate , presence sinus rhythm device-induced rhythm , QRS duration ) ; Echocardiogram ( assessment leave ventricular end-diastolic end-systolic volume , leave ventricular ejection fraction ) ; Electronic device control ( assessment right ventricular stimulation percentage ; electrical parameter arrhythmias diagnostic data ) . MLHFQ One year office follow-up : Clinical visit : NYHA class , comorbidities , echocardiographic parameter , drug therapy , cardiovascular hospitalization last three month . Rest ECG ( assessment rest heart rate , presence sinus rhythm device-induced rhythm , QRS duration ) ; Electronic device control ( assessment right ventricular stimulation percentage ; electrical parameter arrhythmias diagnostic data ) . Echocardiogram ( assessment leave ventricular end-diastolic end-systolic volume , leave ventricular ejection fraction ) ; MLHFQ</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>Age ≥ 18 year . Patients stable chronic heart failure implant monocameral bicameral ICD home monitoring remote control . Moderate severe leave ventricular dysfunction ( FE ≤ 40 % ) . Any cause heart failure allow apart congenital heart disease . Bicameral ICD program DDD AAI/DDD AV interval &lt; 300 msec . Rest ECG heart rate ≥70 bpm ; Sinus rhythm . In therapy lowdose betablocker ( bisoprolol 1,252,5 mg ) maximum dose tolerate angiotensinconverting enzyme inhibitor blockade angiotensin II receptor , mineralocorticoid antagonist , antiplatelet lipidlowering therapy , unless contraindicate . Inability provide informed consent ; Age &lt; 18 year . State pregnancy lactation . Recent ( &lt; 2 month ) myocardial infarction ; Contraindications betablockers ivabradine ; Rest ECG heart rate &lt; 70 bpm ; No sinus rhythm . Administration nondihydropyridinic calcium channel antagonist , digitalis , class I antiarrhythmic drug , strong inhibitor cytochrome P450 3A4 time enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>